Objective To investigate the effect of rosuvastain on the lung function and quality of life in patients with stable chronic obstructive pulmonary disease(COPD).Methods 88 patients with COPD were selected, they were divided into the research group and the control group by digital table method,each group had 44 cases. Traditional treatment was used to treat patients in the control group,the research group was treated with rosuvastain 20mg,1 time one day on the basis of the traditional treatment,all patients were treated for 6 months.Before treatment, 1 month after therapy and 6 months after therapy,the first second forced expiratory volume(FEV1 ),forced expiratory volume in first second(FEV1 ),forced vital capacity(FVC%)value and the patients'lung function were determined, the patients'quality of life was evaluated by the COPD Assessment Test (CAT).Results After1 and 6 months of therapy,the FEV1 ,FEV1/FVC of the two groups were higher than before treatment,and after 6 months of therapy,the FEV1,FEV1/FVC of the research group were (1.49 ±0.40)L,(59.35 ±5.51)% respectively,which were significantly higher than (1.28 ±0.31)L,(53.02 ±5.60)% of the control group(t=2.753,5.345,all P<0.05). After 1 and 6 months of therapy,the CAT scores of the two groups were lower than before treatment,and after 6 months of therapy,the CAT score of the research group was (17.27 ±3.32)points,which was significantly lower than (21.25 ± 4.51)points of the control group(t=-4.714,P<0.05).Conclusion Rosuvastain can improve lung function and quality of life in patients with COPD,the clinical curative effect is distinct,and it is worthy of popularization and application.